Paul Stang

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Epidemiological context of signalling
    Paul Stang
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    Drug Saf 30:611-3. 2007
  2. ncbi Comparison of methods for correcting population stratification in a genome-wide association study of rheumatoid arthritis: principal-component analysis versus multidimensional scaling
    Dai Wang
    Department of Pharmacogenomics, Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08869 USA
    BMC Proc 3:S109. 2009
  3. ncbi Genome-wide association study for empirically derived metabolic phenotypes in the Framingham Heart Study offspring cohort
    Marsha Wilcox
    Epidemiology, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Road, PO Box 200, M S K304, Titusville, New Jersey 08560 USA
    BMC Proc 3:S53. 2009
  4. ncbi Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication
    Michael Von Korff
    Center for Health Studies, Group Health Cooperative, 1730 Minor Avenue Suite 1600, Seattle, WA 98101, USA
    Pain 113:331-9. 2005
  5. ncbi Guidelines for good pharmacoepidemiology practices (GPP)
    Elizabeth B Andrews
    Pharmacoepidemiol Drug Saf 17:200-8. 2008

Collaborators

  • Jesse A Berlin
  • Patrick Waller
  • Michael Von Korff
  • B L Strom
  • Alexander M Walker
  • Robert C Nelson
  • Dai Wang
  • Yu Sun
  • Marsha Wilcox
  • Qingqin Li
  • Elizabeth B Andrews
  • Marsha A Wilcox
  • Nancy Santanello
  • Gretchen S Dieck
  • Stephan Lanes
  • Susana Perez-Gutthann
  • David W Kaufman
  • Robert Chen
  • Francisco J de Abajo
  • Byung-Joo Park
  • Joel Freiman
  • Susan Sacks
  • Linda Koo
  • Anne Trontell
  • Karen Wilcock
  • Edward A Bortnichak
  • Corinne de Vries
  • Wanju S Dai
  • Judith K Jones
  • Allen A Mitchell
  • Ineke Neutel
  • Xavier Kurz
  • Suzanne West
  • Jerry Avorn
  • Robert P Wise
  • Douglas J Watson
  • Andrew Stergachis
  • Stanley Edlavitch

Detail Information

Publications5

  1. ncbi Epidemiological context of signalling
    Paul Stang
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    Drug Saf 30:611-3. 2007
    ....
  2. ncbi Comparison of methods for correcting population stratification in a genome-wide association study of rheumatoid arthritis: principal-component analysis versus multidimensional scaling
    Dai Wang
    Department of Pharmacogenomics, Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08869 USA
    BMC Proc 3:S109. 2009
    ....
  3. ncbi Genome-wide association study for empirically derived metabolic phenotypes in the Framingham Heart Study offspring cohort
    Marsha Wilcox
    Epidemiology, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Road, PO Box 200, M S K304, Titusville, New Jersey 08560 USA
    BMC Proc 3:S53. 2009
    ..The directional findings will provide the basis for hypothesis generation for syndromes such as the metabolic syndrome and obesity...
  4. ncbi Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication
    Michael Von Korff
    Center for Health Studies, Group Health Cooperative, 1730 Minor Avenue Suite 1600, Seattle, WA 98101, USA
    Pain 113:331-9. 2005
    ..The societal burdens of chronic spinal pain need to be understood and managed within the context of comorbid conditions...
  5. ncbi Guidelines for good pharmacoepidemiology practices (GPP)
    Elizabeth B Andrews
    Pharmacoepidemiol Drug Saf 17:200-8. 2008